Monoclonal antibody targets and indications
By: A. Doig, et al
Reprinted with the permission of American Pharmaceutical Review, 2015 Jul-Aug
Since the approval of Orthoclone OKT3 in 1986, the therapeutic monoclonal antibody industry has experienced three decades of continued growth. Today there are over 40 market approved products in the US and EU. This analysis indicates that the growth of therapeutic MAb’s is likely to continue as a number of late-stage product development programs involve novel molecular targets and therapeutic indications. This activity points to an increase in the number of indications that will be treated successfully with MAb therapeutics in the future. The growth in treatment indications and the focus on biosimilars as described in this article will likely increase the demand for manufacturing capacity needed to produce monoclonal antibodies.